Everyone seems to be asking the same question right now: how fast can we get into peptides?

I keep thinking we should be asking something else. Why are we in such a hurry?

I have been in compounding pharmacy for more than 25 years, and I have seen this movie before. A category gets hot. Demand jumps. Patients start asking for it. Clinics see opportunity, telehealth companies see scale and pharmacies see volume. Suddenly everyone wants to move, fast.

That is usually the moment when I get nervous. Not because I am against peptides. I am not. I think there is real potential here. But potential and readiness are not the same thing.

What changed this fall

On October 29, 2026, the U.S. Department of Health and Human Services released an interim policy covering six peptides. It sets conditions under which 503A pharmacies may compound them for individual patients while a permanent decision is made. The conditions start with the ingredient: qualified sourcing, testing and certificates of analysis, and reporting of serious adverse events and product-quality problems.

The first question most people asked was how soon they could launch. The more useful questions are what the conditions actually require, and what each state board thinks about any of it.

State boards of pharmacy are not bound by the federal policy, and they are already taking different approaches. The reporting systems the policy depends on are still being worked out. None of that is a reason to ignore the opportunity. All of it is a reason to slow down long enough to understand it.

Where is the ingredient coming from?

This is the first question to ask, and right now it deserves the closest look.

In a recent call with an API supplier, we walked through what it takes to qualify a peptide ingredient: process development and pilot batches, validated testing methods, batches made under good manufacturing practice, an impurities study that can run for more than a year, and a stability study that runs for years, followed by the documentation. Some of those steps can run in parallel, and some suppliers have already finished the research-use-only phase. Until the end of that path, the material is labeled for research and development use only, not for human use.

So if a supplier tells you, days after the policy was released, that its peptide already meets the new conditions, or offers to sell it to you now, be cautious. Ask to see every step, with documents. A certificate of analysis is only as reliable as the source behind it. We wrote up the questions to ask a peptide API supplier on the pharmacy site.

The questions that come before a launch date

Before anyone starts talking about launch dates, I want to know a few things.

Where is the API coming from? Can you actually verify identity, purity and potency?

Who understands the formulation? Who understands stability?

Who is educating the prescriber? Who is setting expectations with the patient?

How are you handling complaints? How are you tracking adverse events?

What happens when something changes? What happens when something goes wrong?

Those questions are not nearly as exciting as how fast we can launch. They are a lot more important.

Speed is not the same as progress

Here is the part that worries me most. In healthcare, speed can look a lot like progress. It is not always the same thing.

You can move quickly and still build something badly. You can have demand and still not have a real program. You can have patients asking for something and still not be ready to responsibly provide it. And you can make money in the short term while creating a mess you will spend years cleaning up.

That is not the kind of growth I am interested in. I am much more interested in building something that lasts: something physicians trust, something patients trust, something our own clinical teams can stand behind, and something we will still be proud of five years from now.

Readiness, in practice

Readiness is not a feeling. It is a list of things that are true before the first prescription arrives.

Sourcing: you know who made the ingredient, you can trace it from that manufacturer to the pharmacy, and the documents hold up.

Formulation and quality: the pharmacy has worked out the preparation, knows how it holds up over time, and can show how it checks what it makes. How an outside survey looks at that is described in inside PCAB accreditation.

Prescriber support and patient expectations: prescribers know what the program does and does not do, and patients hear the same thing from the clinic and the pharmacy.

Reporting and follow-up: there is a named person who receives complaints and adverse-event reports and knows where they go, even while the national reporting systems are still being built.

State rules: you know what each state where your patients live has said, and you have a plan for the states that have not said anything yet.

Most of this is the same groundwork as any program launch, covered in clinic onboarding: what makes it fast. It is just under a brighter light right now.

Start with the right question

I am not skeptical of peptides. I am skeptical of hype. And right now, there is a lot of hype.

So if you are thinking about building a peptide program, maybe do not start with how fast you can launch. Start with whether you are actually ready. That question may slow you down for a minute. Good. It probably should.

If you are a physician, clinic, telehealth company or healthcare organization thinking about this, I am happy to talk through what needs to be in place before you launch. Not the hype. The real work: sourcing, formulation, quality, prescriber support, patient expectations and operational readiness. If you are trying to build it correctly, start a conversation with the ProCompounding team.

COMMON QUESTIONS

What did the October 2026 HHS peptide policy do?

It is an interim policy covering six peptides. It sets conditions under which 503A pharmacies may compound them for individual patients while a permanent decision is made, starting with qualified ingredient sourcing, testing and certificates of analysis, and reporting of serious adverse events and product-quality problems.

Does the federal policy settle the question in every state?

No. State boards of pharmacy are not bound by it and are taking different approaches. A program has to account for the rules in every state where its patients live.

What should a clinic ask before starting a peptide program?

Where the ingredient comes from and how its identity, purity and potency are verified; who understands the formulation and its stability; who educates prescribers and sets patient expectations; and how complaints and adverse events are handled.

Why be cautious about a supplier that says its peptide is ready now?

Qualifying a peptide ingredient takes a long sequence of development batches, manufacturing batches, studies and documentation, and some of those studies run for more than a year. Material made before that path is finished is labeled for research use only. A supplier claiming full readiness days after the policy should be able to document every step.